ClinicalTrials.gg
RecruitingNCT07950072Updated Nov 20, 2026

Study Aims to Compare the Use of Systemic Steroids, to the Combination of Systemic Steroids and Methotrexate and to the Combination of Systemic Steroids With Methotrexate and Mycophenolate Mofetil in the Treatment of Idiopathic Granulomatous Mastitis and to Show Response on Subsequent US Examination

An interventional study of Prednisolone and Methotrexate in Idiopathic Granulomatous Mastitis, sponsored by Kasr El Aini Hospital. Recruiting at 1 site in Egypt. Open to female participants. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Kasr El Aini Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 4 months after the study started (first participant enrolled Jul 2025, registered Nov 2026).
  • Started Jul 2025; still recruiting 1 year 4 months later.
Updated Nov 20, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Non-randomized
Sex
Female
01

Study summary

The present study aims to compare the use of systemic steroids, to the combination of systemic steroids and methotrexate and to the combination of systemic steroids with methotrexate and mycophenolate mofetil in the treatment of idiopathic granulomatous mastitis. Also, this study aims to show the response to medical treatment on subsequent US examinations.

02

Conditions studied

  • Idiopathic Granulomatous Mastitis

Browse trials for

Keywords

  • granulomatous mastitis steroids
03

In context

Granulomatous Mastitis

23 studies on the registry are indexed under Granulomatous Mastitis; 8 are open to participants now.

This study's planned enrollment of 90 is above the median of 72 across 13 interventional studies indexed under Granulomatous Mastitis.

Browse Granulomatous Mastitis studies →

Lead sponsor

Kasr El Aini Hospital is the lead sponsor of 288 studies on the registry; 35 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histopathological evidence of IGM.

Exclusion criteria

Exclusion Criteria:

  • . Pregnancy Lactation
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    one (Monotherapy)

    30 female patients with histopathologically confirmed idiopathic granulomatous mastitis

    Drug: Prednisolone

  • Experimental
    two (Double Therapy)

    30 female patients with histopathologically confirmed idiopathic granulomatous mastitis

    Drug: Prednisolone · Drug: Methotrexate

  • Experimental
    Three (Triple Therapy)

    30 female patients with histopathologically confirmed idiopathic granulomatous mastitis

    Drug: Prednisolone · Drug: Methotrexate · Drug: Mycofenolate mofetil

Interventions

  • Systemic prednisolone at an initial dose of 30 mg/day

  • Systemic prednisolone (30 mg/day) combined with oral/subcutaneous methotrexate (25 mg/week) plus folic acid supplementation (10 mg/week).

  • DrugMycofenolate mofetil

    Systemic prednisolone (30 mg/day), methotrexate (25 mg/week with folic acid), and mycophenolate mofetil (1g/day in divided doses)."

06

What researchers measure

Primary outcomes

  1. Complete Response

    Defined as achieving both complete clinical and radiologic remission at 6 months

    Time frame: 6 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2025 (actual). Primary completion is estimated for Dec 2026, 17 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2026
First posted
Nov 20, 2026
StartActual
Jul 1, 2025
Primary completionEst.
Dec 1, 2026
CompletionEst.
Dec 1, 2026
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07950072
Responsible party
Mohannad Fayed (Lecturer of General Surgery, Kasr El Aini Hospital) — Principal investigator
First posted
Nov 20, 2026
Start date
Jul 1, 2025
Primary completion
Dec 1, 2026 (estimated)
Completion
Dec 1, 2026 (estimated)
Last update
Nov 20, 2026

Study contacts

Mohannad Aly Fayed, Lecturer
Contact
dr.mohannad.fayed@gmail.com
00201009373070

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Methotrexate

Start the discussion